Pfizer Inc.

New York, NY: (Apr-02-07) The Department of Justice began an investigation into the off-label marketing of Pfizer's human-growth hormone brand, Genotropin, alleging that a unit of the company made kickbacks to an outside vendor in order to increase its sales. Pfizer admitted that Pharmacia, one of its acquired companies improperly promoted Genotropin between January 2000 and March 2003 for anti-aging purposes, improved athletic performance, and enhanced appearance. In a settlement reached, Pfizer agreed to pay $34.7 million to end the investigation. [BRANDWEEK: GENOTROPIN SETTLEMENT]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on Apr-5-07